ACT-500
/ Xiamen Amoytop Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 08, 2025
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
1 to 1
Of
1
Go to page
1